ASX ANNOUNCEMENT 15 January 2025 Partial Exercise of Over-Allotment Option and End of Stabilisation Period Partial Exercise of the over-allotment option Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) ( Anteris

of Over-Allotment Option and End of Stabilisation Period

of the over-allotment option

Anteris Technologies

Global Corp. (NASDAQ: AVR, ASX: AVR) (Anteris or the Company) advises that, in connection with its initial public offering

in the U.S. which closed on 16 December 2024 (U.S. time), TD Cowen, Barclays and Cantor (the Underwriters' Representatives)

have partially exercised the over-allotment option granted by the Company in respect of 78,481 shares of common stock of the Company

(Common Stock) at the purchase price of US$6.00 per share, less underwriting discounts and commissions of $0.42 per share. The

portion of the over-allotment option that was not exercised by the Underwriters' Representatives lapsed on 11 January 2025

(U.S. time). Closing and settlement of the exercised portion of the over-allotment option occurred on 14 January 2025 (U.S. time).

End of Stabilisation

to the no-action letter' issued by the Australian Securities and Investments Commission in connection with the Company's

initial public offering in the U.S. (No Action Letter).

the market stabilisation arrangements regarding the Company's Common Stock, the Company confirms that TD Cowen (Stabilisation

Manager) ceased its market stabilisation activities on 12 January 2025, with the stabilisation period in connection the Company's

initial public offering in the U.S. therefore ceasing on 12 January 2025.

the requirements of the No Action Letter, the Company advises that the market stabilisation and related activities undertaken by or on

behalf of the Stabilisation Manager during the stabilisation period were as follows:

Technologies Global Corp. (NASDAQ: AVR, ASX: AVR)

Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and

commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in

Minneapolis, USA (a MedTech hub), Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering

restorative solutions to structural heart disease patients.

lead product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's leading

interventional cardiologists and cardiac surgeons to treat aortic stenosis - a potentially life-threatening condition resulting

from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped

to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.

THV is made using a single piece of molded ADAPT tissue, Anteris' patented anti-calcification tissue technology.

ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000

THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR

and Additional information

was authorised by the Board of Directors.